Keith Flaherty
Fondateur chez Strata Oncology, Inc.
Profil
Keith T.
Flaherty is the founder of X4 Pharmaceuticals, Inc. (founded in 2014) and Strata Oncology, Inc. (founded in 2016) where he holds the title of Director.
Dr. Flaherty is also the founder of Apricity Health LLC, Scorpion Therapeutics, Inc...
Dr. Flaherty's current job(s) include Deputy Chairman at Biomarker Science Group LLC, Director at American Association for Cancer Research, Director-Clinical Research at Massachusetts General Hospital Cancer Center, Editor-in-Chief at Clinical Cancer Research, and Professor at Harvard Medical School.
Dr. Flaherty's former job(s) include Independent Director at Clovis Oncology, Inc. (2013-2023), Director at Loxo Oncology, Inc. (2013-2019), Independent Director at Checkmate Pharmaceuticals, Inc. (2019-2022), and Independent Director at Kinnate Biopharma, Inc. (2019-2024).
Dr. Flaherty's education history includes an undergraduate degree from Yale University and a doctorate degree from The Johns Hopkins University School of Medicine.
Postes actifs de Keith Flaherty
| Sociétés | Poste | Début |
|---|---|---|
Massachusetts General Hospital Cancer Center
 Massachusetts General Hospital Cancer Center Hospital/Nursing ManagementHealth Services Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/07/2009 |
| Biomarker Science Group LLC | Directeur/Membre du Conseil | - |
| Harvard Medical School | Corporate Officer/Principal | 01/01/2009 |
Strata Oncology, Inc.
 Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI. | Fondateur | 01/01/2016 |
American Association for Cancer Research
 American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | 01/01/2019 |
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Fondateur | - |
| Clinical Cancer Research | Corporate Officer/Principal | - |
Anciens postes connus de Keith Flaherty
| Sociétés | Poste | Fin |
|---|---|---|
| KINNATE BIOPHARMA INC. | Directeur/Membre du Conseil | 03/04/2024 |
| CLOVIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 10/07/2023 |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░ | - |
Formation de Keith Flaherty
| Yale University | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital Cancer Center Hospital/Nursing ManagementHealth Services Massachusetts General Hospital Cancer Center operates as cancer treatment center. The company was founded by John Warren in 1811 and is headquartered in Boston, MA. | Health Services |
| Biomarker Science Group LLC | |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
Strata Oncology, Inc.
Strata Oncology, Inc. Pharmaceuticals: MajorHealth Technology Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI. | Health Technology |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
American Association for Cancer Research
American Association for Cancer Research Miscellaneous Commercial ServicesCommercial Services American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA. | Commercial Services |
Kinnate Biopharma, Inc.
 Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Technology |
Apricity Health LLC
 Apricity Health LLC Miscellaneous Commercial ServicesCommercial Services Apricity Health LLC is a digital health company that aims to bridge the gap between academic specialty care and real-world practice. The company is based in Houston, TX. Apricity Health is committed to disseminating clinical expertise to benefit patients everywhere, especially those without access to subspecialty care. Apricity Health develops digital solutions to make novel life-saving cancer therapies safer, better, and more accessible to patients. The company was founded by world-renowned physician scientists in cancer and immuno-oncology, including Keith T. Flaherty, James Allison, Lynda Chin, and Padmanee Sharma. Lynda Chin has been the CEO since incorporation. | Commercial Services |
| Clinical Cancer Research |
